Aquatic Capital Management LLC Buys New Shares in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Aquatic Capital Management LLC purchased a new position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 57,610 shares of the company's stock, valued at approximately $456,000.

Several other institutional investors also recently modified their holdings of the stock. MetLife Investment Management LLC grew its holdings in shares of Amneal Pharmaceuticals by 2.5% in the 4th quarter. MetLife Investment Management LLC now owns 94,639 shares of the company's stock worth $750,000 after acquiring an additional 2,297 shares during the last quarter. Franklin Resources Inc. increased its stake in Amneal Pharmaceuticals by 4.9% in the 3rd quarter. Franklin Resources Inc. now owns 89,887 shares of the company's stock worth $778,000 after purchasing an additional 4,178 shares in the last quarter. Arizona State Retirement System raised its holdings in Amneal Pharmaceuticals by 13.6% during the 4th quarter. Arizona State Retirement System now owns 40,401 shares of the company's stock worth $320,000 after buying an additional 4,851 shares during the period. Alliancebernstein L.P. lifted its stake in Amneal Pharmaceuticals by 2.5% during the fourth quarter. Alliancebernstein L.P. now owns 200,246 shares of the company's stock valued at $1,586,000 after buying an additional 4,927 shares in the last quarter. Finally, Globeflex Capital L P boosted its holdings in shares of Amneal Pharmaceuticals by 3.8% in the fourth quarter. Globeflex Capital L P now owns 144,439 shares of the company's stock worth $1,144,000 after buying an additional 5,245 shares during the period. Institutional investors own 31.82% of the company's stock.

Insider Buying and Selling at Amneal Pharmaceuticals

In other news, major shareholder Tushar Bhikhubhai Patel sold 5,000,000 shares of the company's stock in a transaction dated Friday, March 14th. The stock was sold at an average price of $8.35, for a total transaction of $41,750,000.00. Following the completion of the sale, the insider now owns 48,578,209 shares in the company, valued at approximately $405,628,045.15. This represents a 9.33 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Gautam Patel sold 80,000 shares of the stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $8.90, for a total value of $712,000.00. Following the transaction, the director now directly owns 1,808,886 shares in the company, valued at approximately $16,099,085.40. This represents a 4.24 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 5,160,000 shares of company stock worth $43,113,200 over the last ninety days. 26.56% of the stock is currently owned by insiders.

Amneal Pharmaceuticals Trading Up 3.0 %

NASDAQ AMRX opened at $7.97 on Friday. Amneal Pharmaceuticals, Inc. has a 1-year low of $5.81 and a 1-year high of $9.48. The firm's fifty day simple moving average is $8.02 and its 200-day simple moving average is $8.17. The company has a market capitalization of $2.47 billion, a PE ratio of -11.72 and a beta of 1.17.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last issued its earnings results on Friday, May 2nd. The company reported $0.19 earnings per share for the quarter, topping the consensus estimate of $0.14 by $0.05. Amneal Pharmaceuticals had a negative return on equity of 346.26% and a negative net margin of 6.88%. As a group, analysts predict that Amneal Pharmaceuticals, Inc. will post 0.53 EPS for the current year.

Wall Street Analyst Weigh In

AMRX has been the subject of several research analyst reports. JPMorgan Chase & Co. upgraded shares of Amneal Pharmaceuticals from a "neutral" rating to an "overweight" rating and upped their price target for the company from $9.00 to $12.00 in a research report on Monday, February 24th. Barclays raised their target price on Amneal Pharmaceuticals from $10.00 to $11.00 and gave the stock an "overweight" rating in a research report on Monday, March 3rd. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of "Buy" and an average price target of $10.80.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.

Want to see what other hedge funds are holding AMRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.